Systemic Lupus Erythematosus with Sensorineural Hearing Loss and Improvement after Plasmapheresis Using the Double Filtration Method

Sentaro Kobayashi, Noboru Fujishiro and Kazuko Sugiyama*

A 32-year-old female was diagnosed as having systemic lupus erythematosus based on her laboratory tests. In 1985 she began to complain of hearing difficulty. Her hearing ability deteriorated to the extent that her audiogram revealed a hearing loss of 90db to 110db in both ears in September 1989. She received two series of plasmapheresis treatments using the double filtration method. After two series of plasmapheresis treatments, her hearing improved dramatically. This improvement suggests that circulating immune complexes and anti-phospholipid antibodies might play a pathological role in the hearing impairment in SLE patient.

Key words: anti-phospholipid antibodies, cerebral thrombosis, double filtration method, epilepsy, immune complexes, micro-circulation

Case Report

A-32-year-old female first consulted her physician because of palmar erythema in 1983. She was diagnosed as having systemic lupus erythematosus (SLE) based on her serological analysis. Fever, hand edema, proteinuria, arthralgia and myalgia were also present. A butterfly rash and an increased blood sedimentation rate were also observed. She was treated with a low dosage of steroids for a short period.

She was referred to our hospital three months later. Her laboratory findings were positive for anti-DNA antibodies and anti-nuclear antibodies and a consistently low level of complements. Echocardiographic examination of her heart showed mild mitral regurgitation and a small verruca under the frontal leaf of the mitral valve. In 1988 she experienced convulsions, and her electroencephalogram showed the typical spike-and-wave pattern observed in epilepsy. Her brain CT scan showed a small low density area near the left ventricle of the cerebrum.

She began to complain of hearing difficulties in 1985. In spite of intensive treatment, including steroids, her hearing deteriorated gradually to the extent that her audiogram revealed losses of 100db in both ears by September 1989. She received two series of plasmapheresis treatments using the double filtration method at the end of 1989. Each series of plasmapheresis treatments lasted 4 consecutive days. After the second series of plasmapheresis, her hearing improved dramatically.

There was no history of any particular diseases in her family. Her physical findings at admission were a systolic murmur at the base of her heart and no palpable lymph nodes. The liver and spleen were not enlarged. She had a consistent low grade fever which was not controlled by steroids.

Laboratory Tests

Laboratory tests were performed prior to plasmapheresis treatment in November 1989 and the results were as follows: Urinalysis was negative for protein, glucose and bile. Her urinary sediments were normal. Hematological findings disclosed that her hemoglobin was 12.9g/dl, the red cell count $398 \times 10^4$mm$^3$, the white cell count 6,200 and the platelet count was 225,000. Prothrombin time was 15.4 seconds. Activated partial thromboplastin time was prolonged at 61.6 seconds. Lupus anti-coagulant tests were positive and anti-phospholipid antibodies such as anti-phosphatidyl serine antibody, anti-cardiolipin, anti-phosphatidyl inositol, phosphatidyl glycerol and phosphatidic acid were also positive. Anti-
nuclear antibodies were positive (×640). The anti-DNA antibody for double stranded DNA was 0.4 U/ml, and the antibody for the anti-single stranded DNA was 5.7 U/ml. Serum complement levels were consistently low; C3 30.8 mg/dl, C4 7.3 mg/dl, and CH50 27.7 U/ml. The immune complex level, measured by Clq binding assay (1), was 22.7 μg/ml (normal ≤35.5). Her serum total protein was 6.9 g/dl, serum albumin 4.4 g/dl, GOT 108 IU/l, GPT 4 KU/ml, LDH 385 IU/l, amylase 108 IU/l, CPK 39 IU/l, BUN was 11.1 mg/dl, creatinine 1.58 mg/dl, Na 139.4 mEq/l, K 3.4, Cl 95, Ca 9.5 mg/dl, P 5.2 mg/dl and total cholesterol 177 mg/dl. Her cerebrospinal fluid showed total protein of 33 mg/dl, with a relatively high content of IgG, 4.122 mg/dl; normal IgA, 0.225 mg/dl; and IgM, 0.06 mg/dl.

The echocardiogram revealed mild mitral regurgitation and a small verruca under the frontal leaf of the mitral valve. The patient’s electroencephalogram in 1988 showed the typical spike-and-wave pattern of epilepsy (Fig. 1). The audiogram showed sensorineural hearing loss of 90 to 110 db in both ears (Fig. 2).

**Plasmapheresis**

Plasmapheresis was performed by the double filtration method (2) using KM8800 apparatus (Kurare). A polyvinyl-alcohol membrane was used for the first filter as the plasmaseparator, and an ethylene vinyl-alcohol membrane was used as the second filter to separate the macromolecules with a molecular weight of larger than 2 x 10^6. Simultaneously 700 ml of serum was discarded and replaced by 700 ml of fluid containing 4.4% albumin. This plasmapheresis treatment was performed for 4 consecutive days.

The patient’s hearing at the onset of the disease was normal, but there was a gradual loss of 60 to 70 db in the middle tones in 1986 and 110 db loss was observed in September 1989 (Fig. 2). This hearing impairment necessitated the use of a hearing aid.

The first series of plasmapheresis treatments was performed at the end of 1989. Her hearing improved dramatically after the first series of plasmapheresis as recorded in her audiogram (Fig. 3). After the second series of plasmapheresis, her hearing loss improved to 40 to 60 db, the level similar to that observed in 1986. This improvement lasted for several weeks and the severe hearing loss observed in September 1989 never recurred.

Prior to the treatment, her serum immune complex level was 22.7 μg/ml and was reduced to less than 10 μg/ml after the first series of plasmapheresis. The titer levels of anti-nuclear antibody and the level of complements and anti-DNA antibodies did not change remarkably after plasmapheresis. The positive level of anti-phospholipid antibodies did become negative after two series of plasmapheresis (Fig. 4).

**Discussion**

Bowman et al (3) reported that hearing loss is observed in 8% of SLE patients. Hearing loss in these cases was not related to age, sex, disease activity, duration of symptoms of SLE, or to other organ-system involvement such as kidney and brain. They emphasized the importance of audiological screening tests in SLE patients. One case of SLE with hearing impairment reported by Caldarelli et al (4), showed no hearing improvement after treatment with prednisolone and cyclophosphamide. Another case of hearing loss, caused by an autoimmune mechanism affecting the inner ear, was reported to have responded favorably to steroids and immunosuppressive reagents (5).

Successful treatment of systemic vascular diseases by plasma exchange was first reported by Lookwood et al (6). Hamblin et al (7) showed that hearing loss of an SLE patient was improved temporarily by plasmapheresis treatment. The present study also disclosed that plasmapheresis using the double filtration method was effective in improving the hearing ability of our patient. The mechanism of hearing loss in SLE has not been fully investigated. It has been suggested that the occurrence of thrombosis is related to the presence of anti-phospholipid antibodies (8). In the present study, the detection of anti-phospholipid antibodies in the...
serum was positively shown to relate to the patient's complications such as cerebral thrombosis and epilepsy. Carreras and Vermylen have suggested that the anti-phospholipid antibodies might cause the endothelial cell damage which results in decreased prostacyclin production (9). Decreased prostacyclin levels would result in increased platelet aggregation and thrombosis.

Although there is no direct evidence of the relationship between the presence of anti-phospholipid antibodies and the hearing loss in the present case, the improvement in the level of immune complex and anti-phospholipid antibodies after plasmapheresis treatment strongly supports the theory that macromolecules, including anti-phospholipid antibodies, might play a pathological role in micro-circulation in the inner ear and impairment of hearing in SLE patients.

Treatment of hearing impairment in SLE patients is known to be a difficult problem. In addition to plasmapheresis treatment, which was proved to be effective in the present case, the use of anticoagulant and anti-platelet reagents should be considered if abovementioned disease mechanism is one of the causative factors. In order to elucidate the mechanism of hearing loss in SLE, future investigation should include the macro-
Plasmapheresis of SLE with Hearing Loss

molecules obtained in the fraction discarded during plasmapheresis.

References